Learn More About Dr. Germano

Dr. Germano's CV
Don't have PDF Reader? Download one for free to view Dr. Germano's CV.
acrobat reader

Wikipedia page:
/wiki/Isabelle_M._Germano

About Dr. Germano

Isabelle M. Germano, MD is a Tenured Professor of Neurosurgery, Neurology, and Oncological Sciences, in the Department of Neurosurgery at Mount Sinai School of Medicine, New York, NY.

An internationally recognized neurosurgeon, Dr. Germano earned her MD at the University of Torino Medical School, Torino, Italy where she graduated valedictorian in 1984 with a neuroscience thesis on brain tumors histology. She then started a Neurology Residency at the same institution and was awarded a basic science grant on brain tumors. As part of her research, she transferred to the University of California San Francisco (UCSF), CA, where she worked in the Department of Neurosurgery as a researcher until 1987 when she started her Neurosurgery Residency at UCSF.

Dr. Germano continued her training at Zurich University Hospital, Zurich, Switzerland, then at Albert Einstein College of Medicine, New York, NY where she was the recipient of Congress of Neurological Surgeons Clinical Fellowship, and at The Montreal Neurological Institute, Montreal, Canada for a fellowship in epilepsy and movement disorders.

In 1993, Dr. Germano joined the Mount Sinai's Department of Neurosurgery as an Assistant Professor of Neurosurgery, was promoted to Associate Professor in 1997, and Professor in 2005. At The Mount Sinai Hospital, she established the Stereotactic and Image-guided Program, the Comprehensive Brain Tumor Program and the Radiosurgery Program. She is currently the Director of the Comprehensive Brain Tumor Program and Co-Director of the Radiosurgery Program.

Dr. Germano is nationally and internationally acknowledged as a pioneer in neurosurgery image-guidance, brain tumor surgery, and radiosurgery. She is among the first neurosurgeons in the United States to use of computer-assisted image-guided neurosurgery in which sophisticated technology is used to perform minimally invasive surgery for patients with brain tumors, epilepsy, Parkinson's disease and movement disorders. She was instrumental in the development of technology currently widely used by the neurosurgery community, making operations safer and more effective for patients. Her career highlights include conducting the first clinical trial using gene therapy with the adenoviral vector for glioblastoma in NY State (9/1997), the first neurosurgical implant of bilateral STN DBS for Parkinson's disease (7/1995) and Gpi DBS for dystonia (1/1998) in the U.S.

Dr. Germano' s basic science laboratory based on translational research has been active and extramurally funded since her joining Mount Sinai. She is currently the Principal Investigator of a NIH/NCI RO1 research grant focusing on the use of gene therapy delivery by stem cells for malignant brain tumors. She has authored over 100 scientific publications, including over 80 peer-reviewed papers, books, and chapters and maintains the highest impact factor in her department.

Dr. Germano is board certified in neurological surgery by the American Board of Neurological Surgery (ABNS, 1995). Her clinical interests include treatment of brain tumors, particularly those located in eloquent areas of the brain, brain mapping, image-guided tumor resections, minimally invasive neurosurgery, metastatic and primary brain and spine tumors, radiosurgery, meningiomas, pituitary adenomas, arterovenous malformations, degenerative spine diseases.

Dr. Germano has been acknowledged by Castle Connolly as New York Best Doctors, Best Doctors in the New York Metro Area, America's Top Doctors, America's Top Doctors for Cancer, by as Key Professional Media as New York Superdoctors, and by Consumer Research Council as America's Top Surgeon's. She is and has been very active in many organizations, including the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the American Epilepsy Society where she was asked to serve in leadership positions. She is also a voting member of the Food and Drug Administration (FDA) for neurological devices.